CyFlow CD27 Pacific Orange
品番 | BG767161 | ||
---|---|---|---|
抗体名 | Anti-Hu CD27 PAC OR,LT27 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 0.4 ml | ||
関連製品 (アイソタイプコントロール) |
- | ||
反応性|交差吸着 | Human | レーザー | Violet |
抗原 | CD27, T14, S152, TP55, TNFRSF7 | 最大蛍光波長 | 551 nm |
クローン | LT27 | 最大励起波長 | 400 nm |
ホスト | Mouse | 標識/Format | Pacific Orange™ |
アイソタイプ | IgG2a | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD27 PAC OR,LT27
特異性
The mouse monoclonal antibody LT27 recognizes CD27 antigen, a 50-55 kDa type I transmembrane glycoprotein (member of the TNF-receptor superfamily) expressed on medullary thymocytes, peripheral T lymphocytes, some B lymphocytes and NK cells.
抗原情報
CD27 is a transmembrane 55 kDa protein of the nerve growth factor-receptor family, expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells. Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid. This sCD27 is an important prognostic marker of acute and chronic B cell malignancies. RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Kara IO, Sahin B, Gunesacar R: Expression of soluble CD27 and interleukins‑8 and ‑10 in B‑cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv·Ther. 2007·Jan-Feb; 24(1):29‑40. <·PMID:·17526459·>
• Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, Matera R, Gandolfo GM, Musto P: CD27 in B‑cell chronic lymphocytic leukemia: Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica. 1998·May; 83(5):398‑402l. <·PMID:·9658722·>
• van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA: Expression and release of CD27 in human B‑cell malignancies. Blood. 1993·Dec·1; 82(11):3430‑6. <·PMID:·8241510·>
• Yun LW, Decarlo AA, Hunter N: Blockade of protease‑activated receptors on T cells correlates with alterd proteolysis of CD27 by gingipains of Porphyromonas gingivalis. Clin·Exp·Immunol. 2007·Nov; 150(2):217‑29. <·PMID:·17937677·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN